Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion

Regen BioPharma Inc

Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.
6% interest per annum; maturity date August 5, 2026.
Conversion price is 60% of lowest trading price over prior 20 trading days.
Beneficial ownership limitation set at 4.99% (can be increased to 9.99% by holder).
Shares upon conversion are unregistered and subject to restrictive legend.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.